IDH1 Mutant Glioma Favors Group 3 Innate Lymphoid Cells and Is Resistant to Immune Checkpoint Expression.

Area of Science:

• Immunology
• Oncology
• Neuroscience

Background:

• Isocitrate dehydrogenase 1 (IDH1) mutations significantly alter glioma biology and the tumor immune microenvironment.
• The role of innate lymphoid cells (ILCs), crucial for immune responses, in IDH1-mutant gliomas is largely unexplored.

Purpose of the Study:

• To investigate the impact of IDH1 mutations and D-2-hydroxyglutarate (D-2HG) on ILC subsets, immune checkpoint expression, and cytokine production in glioma.
• To elucidate the mechanisms by which IDH1 mutations influence the innate immune landscape within gliomas.

Main Methods:

• Analysis of ILC subsets and immune checkpoint molecules (PD-1, CTLA-4) in tumor and blood samples from 32 glioma patients via flow cytometry.
• Co-culture experiments with human ILCs and IDH1-mutant/wild-type glioma cells/conditioned medium.
• In vitro exposure of ILCs to D-2HG and in vivo administration of D-2HG/L-2HG in mice to assess ILC distribution.

Main Results:

• IDH1-mutant gliomas showed increased ILC3 and decreased ILC1 frequencies, with ILC3s expressing higher PD-1 and ILC2s showing reduced PD-1.
• Glioma cells and D-2HG suppressed ILC immune checkpoint expression (PD-1, CTLA-4) while promoting proliferation and enhancing IFN-γ and TNF-α secretion.
• In vivo administration of D-2HG and L-2HG differentially modulated ILC subset distribution in lymphoid and mucosal tissues.

Conclusions:

• IDH1 mutations and D-2HG reshape the ILC landscape in gliomas, promoting an ILC3-dominant phenotype with diminished immune checkpoint receptor expression.
• These findings highlight ILCs as key players in glioma immunity and suggest targeting innate immune pathways as a potential therapeutic strategy.